Clinical Trials
21 trialsNCT04624204 2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04948333 2026-03-18
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
Novartis
Phase 3 Completed
NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
NCT04487236 2025-08-11
Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors
Suzhou Zanrong Pharma Limited
Phase 1 Completed
NCT06128148 2025-07-14
JYP0322
Guangzhou JOYO Pharma Co., Ltd
Phase 1 Recruiting
NCT04820023 2025-06-06
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
Bridge Biotherapeutics, Inc.
Phase 1/2 Terminated
NCT06082635 2025-05-18
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
Shenzhen TargetRx Co., Ltd.
Phase 3 Active not recruiting
NCT04421222 2025-02-28
EPI-7386
ESSA Pharmaceuticals
Phase 1 Terminated
NCT04515979 2024-12-09
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
MedPacto, Inc.
Phase 2 Terminated
NCT05561374 2024-11-29
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato, Inc.
Phase 1 Active not recruiting
NCT04507919 2024-11-12
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer
Novartis
No longer available
NCT02278250 2023-03-16
First in Human Study of M4344 in Participants With Advanced Solid Tumors
EMD Serono
Phase 1 Completed
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT01976741 2021-05-06
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
Phase 1 Completed
NCT03516071 2019-09-04
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT04015024 2019-07-16
A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT00509821 2019-04-05
Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma
Eli Lilly and Company
Phase 2 Completed
NCT01243346 2018-06-28
Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene
Arog Pharmaceuticals, Inc.
Phase 2 Completed
NCT01433731 2016-03-24
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
TetraLogic Pharmaceuticals
Phase 1 Completed
NCT00751205 2014-10-28
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Bayer
Phase 2 Completed
NCT01254136 2012-01-25
Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
Incyte Corporation
Phase 1/2 Terminated